Multiple Eruptive Dermatofibromas in a Patient with Myasthenia Gravis Treated with Systemic Corticosteroid
- Author:
Geun Hwi PARK
1
;
Taewook KIM
;
Sungmin PARK
;
Hyun Joo LEE
;
Hyunju JIN
;
Woo Haing SHIM
;
Gun Wook KIM
;
Hoon Soo KIM
;
Hyun Chang KO
;
Byung Soo KIM
;
Moon Bum KIM
;
Hyang Suk YOU
Author Information
1. Department of Dermatology, School of Medicine, Pusan National University, Korea. oasis8299@naver.com
- Publication Type:Case Report
- Keywords:
Multiple eruptive dermatofibromas;
Myasthenia gravis;
Immunosuppression
- MeSH:
Autoimmune Diseases;
Female;
Histiocytoma, Benign Fibrous;
Humans;
Immunosuppression;
Immunosuppressive Agents;
Lower Extremity;
Myasthenia Gravis;
Skin
- From:Korean Journal of Dermatology
2019;57(4):194-196
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Dermatofibroma is a fibrohistiocytic tumor of the skin that commonly occurs as a solitary lesion on the lower extremities of young women. Multiple eruptive dermatofibromas (MEDFs), defined as the presence of 5 to 8 dermatofibromas appearing within a period of 4 months, are rare, and the etiology of MEDFs remains unknown. However, MEDFs are frequently thought to be associated with altered immunity, such as autoimmune diseases and immunosuppression. It is unclear why MEDFs occur in association with these conditions, but this relationship may suggest that MEDFs are the result of an abortive immunoreactive process. We herein describe a middle-aged woman who developed multiple dermatofibroma. She had myasthenia gravis for 8 years, and developed MEDFs after undergoing oral corticosteroid treatment (245 mg/week) for 3 months. Therefore, our case suggests that the use of immunosuppressants is a more dominant factor for the development of MEDFs than underlying autoimmune diseases.
